Elena Tsoy1, Amelia Strom1, Leonardo Iaccarino1, Sabrina J Erlhoff1, Collette A Goode1, Anne-Marie Rodriguez1, Gil D Rabinovici1,2, Bruce L Miller1,3, Joel H Kramer1,3, Katherine P Rankin1, Renaud La Joie1, Katherine L Possin4,5. 1. Department of Neurology, Memory and Aging Center, University of California San Francisco, Box 1207, 675 Nelson Rising Lane, Suite 190, San Francisco, CA, 94158, USA. 2. Department of Radiology and Biomedical Imaging, University of California San Francisco, 1500 Owens Street, 2nd Fl, San Francisco, CA, 94158, USA. 3. Global Brain Health Institute, University of California San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA. 4. Department of Neurology, Memory and Aging Center, University of California San Francisco, Box 1207, 675 Nelson Rising Lane, Suite 190, San Francisco, CA, 94158, USA. katherine.possin@ucsf.edu. 5. Global Brain Health Institute, University of California San Francisco, 675 Nelson Rising Lane, San Francisco, CA, 94158, USA. katherine.possin@ucsf.edu.
Abstract
BACKGROUND: β-amyloid (Aβ) and tau positron emission tomography (PET) detect the pathological changes that define Alzheimer's disease (AD) in living people. Cognitive measures sensitive to Aβ and tau burden may help streamline identification of cases for confirmatory AD biomarker testing. METHODS: We examined the association of Brain Health Assessment (BHA) tablet-based cognitive measures with dichotomized Aβ -PET status using logistic regression models in individuals with mild cognitive impairment (MCI) or dementia (N = 140; 43 Aβ-, 97 Aβ+). We also investigated the relationship between the BHA tests and regional patterns of tau-PET signal using voxel-wise regression analyses in a subsample of 60 Aβ+ individuals with MCI or dementia. RESULTS: Favorites (associative memory), Match (executive functions and speed), and Everyday Cognition Scale scores were significantly associated with Aβ positivity (area under the curve [AUC] = 0.75 [95% CI 0.66-0.85]). We found significant associations with tau-PET signal in mesial temporal regions for Favorites, frontoparietal regions for Match, and occipitoparietal regions for Line Orientation (visuospatial skills) in a subsample of individuals with MCI and dementia. CONCLUSION: The BHA measures are significantly associated with both Aβ and regional tau in vivo imaging markers and could be used for the identification of patients with suspected AD pathology in clinical practice.
BACKGROUND: β-amyloid (Aβ) and tau positron emission tomography (PET) detect the pathological changes that define Alzheimer's disease (AD) in living people. Cognitive measures sensitive to Aβ and tau burden may help streamline identification of cases for confirmatory AD biomarker testing. METHODS: We examined the association of Brain Health Assessment (BHA) tablet-based cognitive measures with dichotomized Aβ -PET status using logistic regression models in individuals with mild cognitive impairment (MCI) or dementia (N = 140; 43 Aβ-, 97 Aβ+). We also investigated the relationship between the BHA tests and regional patterns of tau-PET signal using voxel-wise regression analyses in a subsample of 60 Aβ+ individuals with MCI or dementia. RESULTS: Favorites (associative memory), Match (executive functions and speed), and Everyday Cognition Scale scores were significantly associated with Aβ positivity (area under the curve [AUC] = 0.75 [95% CI 0.66-0.85]). We found significant associations with tau-PET signal in mesial temporal regions for Favorites, frontoparietal regions for Match, and occipitoparietal regions for Line Orientation (visuospatial skills) in a subsample of individuals with MCI and dementia. CONCLUSION: The BHA measures are significantly associated with both Aβ and regional tau in vivo imaging markers and could be used for the identification of patients with suspected AD pathology in clinical practice.
Authors: Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow Journal: J Am Geriatr Soc Date: 2005-04 Impact factor: 5.562
Authors: R C Petersen; P S Aisen; L A Beckett; M C Donohue; A C Gamst; D J Harvey; C R Jack; W J Jagust; L M Shaw; A W Toga; J Q Trojanowski; M W Weiner Journal: Neurology Date: 2009-12-30 Impact factor: 9.910
Authors: Harald Hampel; Sid E O'Bryant; José L Molinuevo; Henrik Zetterberg; Colin L Masters; Simone Lista; Steven J Kiddle; Richard Batrla; Kaj Blennow Journal: Nat Rev Neurol Date: 2018-11 Impact factor: 42.937
Authors: Dorene M Rentz; Mario A Parra Rodriguez; Rebecca Amariglio; Yaakov Stern; Reisa Sperling; Steven Ferris Journal: Alzheimers Res Ther Date: 2013-11-21 Impact factor: 6.982
Authors: Jenalle E Baker; Yen Ying Lim; Robert H Pietrzak; Jason Hassenstab; Peter J Snyder; Colin L Masters; Paul Maruff Journal: Alzheimers Dement (Amst) Date: 2016-10-18
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Bernard J Hanseeuw; Rebecca A Betensky; Heidi I L Jacobs; Aaron P Schultz; Jorge Sepulcre; J Alex Becker; Danielle M Orozco Cosio; Michelle Farrell; Yakeel T Quiroz; Elizabeth C Mormino; Rachel F Buckley; Kathryn V Papp; Rebecca A Amariglio; Ilse Dewachter; Adrian Ivanoiu; Willem Huijbers; Trey Hedden; Gad A Marshall; Jasmeer P Chhatwal; Dorene M Rentz; Reisa A Sperling; Keith Johnson Journal: JAMA Neurol Date: 2019-08-01 Impact factor: 18.302